Erudio Bio
Erudio is transforming the economics of medicine with our innovative Versatile Smart Assay (VSA), a cutting-edge semiconductor-based multiplexed instrument platform. Our technology enables comprehensive biomarker testing from a single biological sample, facilitating precise diagnoses and reducing the risk of missed or delayed disease identification. Utilizing our patented dynamic force spectroscopy, Erudio's VSA significantly reduces false positives and achieves unparalleled accuracy by measuring the strength of biomarker-antibody binding. This empowers healthcare providers to detect diseases earlier, saving countless lives and preventing unnecessary suffering.
Our Technology
Our innovative patented technology addresses critical limitations in current multiplexed assay methods, opening new possibilities in disease detection and drug development.
Revolutionary Multiplex Testing
Our VSA technology platform enables simultaneous testing for multiple biomarkers from a single biological sample, overcoming the limitations of traditional methods. This breakthrough allows for comprehensive medical testing, early disease detection, and efficient biotech drug development.
Comprehensive Data with Force Spectroscopy
Our patented force spectroscopy technology measures the strength of bonds between biological molecules, filtering out false positives and ensuring accurate results. This innovative approach allows us to perform accurate multiplexed assays despite the difficulties of cross-reactivity and non-specific bindings
Enhanced Data Collection for AI and Machine Learning
With our expanding partnerships, Erudio is poised to generate vast amounts of medical data, driving knowledge discovery through hidden insights and patterns from this extensive biological data.
Our Team
Meet the Team
Meet the brilliant minds driving innovation at Erudio Bio, Inc. Our diverse team of scientists, researchers, and visionaries is dedicated to revolutionizing the biotech industry.
CEO & Founder
Kee-Hyun Paik​
Kee-Hyun Paik is the President and co-Founder of Erudio Bio, Inc. a pioneering biotech company in the San Francisco Bay Area. With over two decades of experience in biotechnology, Kee-Hyun's background includes co-founding Multerra Bio, Inc., postdoctoral research at Stanford University School of Medicine, and sr. engineering roles at Samsung Electronics and ISE Inc. He holds a Ph.D. and M.S. in Electrical and Electronics Engineering from Stanford University and a B.S. from Duke University.
CTO & Co-Founder
Sunghee Yun
Sunghee Yun is the Co-founder and AI Technology & Product Strategy Lead at Erudio Bio, Inc. He has extensive expertise in AI and Convex Optimization, co-founding Gauss Labs and serving as CTO and Chief Applied Scientist. Sunghee has also held leadership roles at SK hynix and led AI projects at Amazon that generated over $200 million in sales. He holds a Ph.D. in Electrical Engineering from Stanford University and is an Adjunct Professor at Sogang University and an Advisory Professor at DGIST.
COO & Co-Founder
Leon Chen
Leon Chen is the co-founder and leads business development and operations at Erudio Bio, Inc., bringing a blend of technical expertise and business acumen to the role. His background includes serving as Director of Product Management at Resilience and holding various leadership positions during a 13-year tenure at Bank of America. Leon holds an MBA in Finance from the USC Marshall School of Business and a BS in Computer Science from Stanford University.
Advisory Board
Ronald W. Davis
​
Prof. Biochemistry and Genetics, Director Stanford Genome Tech Center
$15B+ exits
Michael Cola
​​
CEO AEVI Genomic Medicine, President of Shire plc. ($62B sale to Takeda)
William J. Greenleaf
Prof. Genetics and Applied Physics, Stanford University
Karyn Eliot
​
Retired CIA Sr. Executive
Tim Germann
​
CCO Chief Commercial Officer Carterra Bio